GCM
SMMT icon

Graham Capital Management’s Summit Therapeutics SMMT Stock Holding History

Graham Capital Management’s Portfolio SMMT Stock Details SMMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$175K Buy
+11,987
New +$213K ﹤0.01% 1070
2024
Q2 		– Sell
-18,961
Closed -$78.5K – 1336
2024
Q1 		$78.5K Buy
+18,961
New +$75.4K ﹤0.01% 989

Other funds holding SMMT

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

Graham Capital Management's SMMT Position: Q2 2026 in Review

Graham Capital Management opened a new position in Summit Therapeutics (SMMT) in Q2 2026: 11,987 shares worth $175K. The stake represents ﹤0.01% of the portfolio and ranks #1070 among its holdings. This is a return to the name: Graham Capital Management previously reported a position in SMMT as recently as Q1 2024.

Graham Capital Management first reported a position in SMMT in Q1 2024 and has held it in 2 quarters since. 242 funds tracked by Wall St. Rank hold SMMT as of Q2 2026.

  • Graham Capital Management held 11,987 shares of Summit Therapeutics worth $175K as of Q2 2026.
  • Summit Therapeutics was a new Graham Capital Management position in Q2 2026.
  • Summit Therapeutics made up ﹤0.01% of Graham Capital Management's portfolio in Q2 2026, its #1070 holding.
  • Graham Capital Management first reported a position in Summit Therapeutics in Q1 2024 and has held it in 2 quarters since.
  • 242 funds tracked by Wall St. Rank held Summit Therapeutics as of Q2 2026.

Based on Graham Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.